Patents by Inventor Roberto Burioni

Roberto Burioni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9598482
    Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies described herein, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies described herein. The monoclonal antibodies can also be used for testing antibody preparations to be used as vaccines.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: March 21, 2017
    Assignee: Pomona Ricerca S.r.l.
    Inventors: Roberto Burioni, Massimo Clementi
  • Patent number: 9587011
    Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: March 7, 2017
    Assignee: Pomona Ricerca S.r.l.
    Inventors: Roberto Burioni, Massimo Clementi
  • Publication number: 20160200801
    Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies described herein, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies described herein. The monoclonal antibodies can also be used for testing antibody preparations to be used as vaccines.
    Type: Application
    Filed: March 29, 2016
    Publication date: July 14, 2016
    Applicant: Pomona Ricerca S.r.l.
    Inventors: Roberto Burioni, Massimo Clementi
  • Publication number: 20160060325
    Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines.
    Type: Application
    Filed: November 11, 2015
    Publication date: March 3, 2016
    Applicant: POMONA RICERCA S.R.L.
    Inventors: Roberto Burioni, Massimo Clementi
  • Patent number: 9243054
    Abstract: A monoclonal antibody directed against the influenza A virus is described, which is capable of binding human and animal isolates of influenza A viruses expressing the H1-subtype hemagglutinin. A preferred embodiment is the antibody designated as Fab49, which shows a neutralizing activity against a plurality of influenza A virus isolates expressing the H1-subtype hemagglutinin, including animal-derived isolates. Anti-idiotype antibodies directed against the monoclonal antibody of the invention, immunogenic or vaccine compositions comprising the monoclonal antibody of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibody of the invention. The monoclonal antibody of the invention can also be employed for testing antibody preparations to be used as vaccines.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: January 26, 2016
    Assignee: POMONA RICERCA S.R.L.
    Inventors: Roberto Burioni, Massimo Clementi
  • Patent number: 9200063
    Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: December 1, 2015
    Assignee: POMONA RICERCA S.R.L.
    Inventors: Roberto Burioni, Massimo Clementi
  • Publication number: 20150191530
    Abstract: A human neutralizing monoclonal antibody is directed against the VP1 protein of JC virus. The JC virus is responsible for progressive multifocal leukoencephalopathy (PML). The antibody is used in a therapeutic or prophylactic treatment of a JCV infection or of a disease associated with a JCV infection, such as progressive multifocal leukoencephalopathy (PML). The antibody is also used in the diagnosis of JCV infections or of diseases associated with JCV infections.
    Type: Application
    Filed: June 26, 2013
    Publication date: July 9, 2015
    Inventors: Roberto Burioni, Massimo Clementi
  • Patent number: 8623363
    Abstract: The present invention relates to the monoclonal antibody e20 or a functional fragment thereof as a medicament for the therapeutic treatment and prevention of HCV infections. The e20 antibody is able to bind all of the known HCV genotypes and exhibits a strong neutralising activity against the virus, in particular towards genotypes 1a, 1b, 2a, and 4. A pharmaceutical composition is also described for the treatment or prevention of HCV infections, which comprises the monoclonal antibody e20 or a functional fragment thereof, and pharmaceutically acceptable excipients, carriers or diluents.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: January 7, 2014
    Assignee: Pomona Ricerca S.R.L.
    Inventors: Roberto Burioni, Massimo Clementi
  • Patent number: 8486406
    Abstract: The use of monoclonal antibodies Fab28 and Fab49 for the prophylactic or therapeutic treatment of swine-origin influenza A (H1N1) virus (S-OIV) infections is described, the which virus is responsible for the influenza syndrome commonly known as “swine flu”. Moreover, the use of the above-mentioned antibodies for selecting potential vaccines for active immunization against S-OIV is described.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: July 16, 2013
    Assignee: Pomona Ricerca S.R.L.
    Inventors: Roberto Burioni, Massimo Clementi
  • Patent number: 8367061
    Abstract: Novel anti-idiotype monoclonal antibodies are described which are capable of specifically reacting with the idiotype of human anti-gp120 antibodies, of inhibiting the binding between the gp120 antigen and human anti-gp120 antibodies, and of evoking a neutralising anti-gp120 immune response in an animal host to which they are administered. The anti-idiotype antibodies of the invention can be identified based on the amino acid sequences of the variable portions of their light and heavy chains. In addition, a method for obtaining a panel of anti-idiotype monoclonal antibodies, expression vectors and transformed host cells usable in a recombinant DNA procedure in order to generate the aforesaid anti-idiotype monoclonal antibodies, as well as the therapeutic, prophylactic and diagnostic use of such antibodies are disclosed.
    Type: Grant
    Filed: January 29, 2008
    Date of Patent: February 5, 2013
    Assignee: Pomona Ricera S.R.L.
    Inventors: Roberto Burioni, Massimo Clementi
  • Publication number: 20130022608
    Abstract: Monoclonal antibodies that are full-length IgG-isotype immunoglobulins and that are characterized by a high broad-range neutralizing activity against the influenza A virus and capable of recognizing a specific hemagglutinin epitope that is highly conserved among different influenza A virus subtypes are provided. Also provided are therapeutic, prophylactic and diagnostic uses of such immunoglobulins.
    Type: Application
    Filed: March 25, 2011
    Publication date: January 24, 2013
    Applicant: Pomona Ricerca S.r.l.
    Inventors: Roberto Burioni, Massimo Clementi
  • Publication number: 20120225068
    Abstract: The use of monoclonal antibodies Fab28 and Fab49 for the prophylactic or therapeutic treatment of swine-origin influenza A (H1N1) virus (S-OIV) infections is described, the which virus is responsible for the influenza syndrome commonly known as “swine flu”. Moreover, the use of the above-mentioned antibodies for selecting potential vaccines for active immunization against S-OIV is described.
    Type: Application
    Filed: June 1, 2010
    Publication date: September 6, 2012
    Inventors: Roberto Burioni, Massimo Clementi
  • Publication number: 20120165211
    Abstract: The present invention refers to human antibodies derived from human antibody libraries prepared from atherosclerotic plaques. It further refers to human antibodies able to immunologically recognize both human transgelin or fragments thereof and a protein with at least 50% similarity to OmpK36 (Outer membrane protein, Klebsiella, K36; GI: 295881594) or fragments thereof. Human transgelin is preferably transgelin 1 (Accession N° Q01995, GI:48255907). The antibodies further recognize an antigen in the atherosclerotic plaque and are useful for the preparation of immunodiagnostic reagents or assays to detect atherogenic diseases. The invention also relates to the use of anti-TAGLN monoclonal antibodies, showing cross-reactivity with a bacterial antigen having at least 50% similarity with OmpK36, for detecting antigens in the atherosclerotic plaque or as atherosclerotic related reagents in an immuno-competition assay.
    Type: Application
    Filed: January 13, 2012
    Publication date: June 28, 2012
    Applicant: BRACCO IMAGING S.P.A.
    Inventors: Roberto BURIONI, Filippo CANDUCCI, Massimo CLEMENTI, Federico MAISANO
  • Publication number: 20120115741
    Abstract: The present invention discloses antibodies or fragments thereof able to bind isolated coronary plaque samples and processes for their production using host cells containing DNA sequences encoding for said antibodies of fragments thereof. Methods for screening ligands to said isolated samples are also described, and compositions containing said antibodies are also provided.
    Type: Application
    Filed: March 17, 2010
    Publication date: May 10, 2012
    Applicant: BRACCO IMAGING S.P.A.
    Inventors: Massimo Clementi, Roberto Burioni
  • Publication number: 20110256140
    Abstract: The present invention relates to the monoclonal antibody e20 or a functional fragment thereof as a medicament for the therapeutic treatment and prevention of HCV infections. The e20 antibody is able to bind all of the known HCV genotypes and exhibits a strong neutralising activity against the virus, in particular towards genotypes 1a, 1b, 2a, and 4. A pharmaceutical composition is also described for the treatment or prevention of HCV infections, which comprises the monoclonal antibody e20 or a functional fragment thereof, and pharmaceutically acceptable excipients, carriers or diluents.
    Type: Application
    Filed: December 21, 2009
    Publication date: October 20, 2011
    Inventors: Roberto Burioni, Massimo Clememti
  • Publication number: 20110076265
    Abstract: A monoclonal antibody directed against the influenza A virus is described, which is capable of binding human and animal isolates of influenza A viruses expressing the H1-subtype hemagglutinin. A preferred embodiment is the antibody designated as Fab49, which shows a neutralizing activity against a plurality of influenza A virus isolates expressing the H1-subtype hemagglutinin, including animal-derived isolates. Anti-idiotype antibodies directed against the monoclonal antibody of the invention, immunogenic or vaccine compositions comprising the monoclonal antibody of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibody of the invention. The monoclonal antibody of the invention can also be employed for testing antibody preparations to be used as vaccines.
    Type: Application
    Filed: May 27, 2009
    Publication date: March 31, 2011
    Inventors: Roberto Burioni, Massimo Clementi
  • Publication number: 20110014187
    Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines.
    Type: Application
    Filed: March 16, 2009
    Publication date: January 20, 2011
    Inventors: Roberto Burioni, Massimo Clementi
  • Publication number: 20100316563
    Abstract: A process is provided for the preparation of antibodies or fragments thereof using a prokaryotic host cell containing DNA sequences encoding for said antibodies of fragments thereof, wherein said DNA sequence is derived from a coronary plaque sample. Compositions containing said antibodies are also provided. Ligands to said antibodies and compositions containing said ligands are also described.
    Type: Application
    Filed: September 18, 2008
    Publication date: December 16, 2010
    Applicant: BRACCO IMAGING S.P.A.
    Inventors: Massimo Clementi, Roberto Burioni
  • Patent number: 7811973
    Abstract: The present invention provides novel technologies for producing and screening fusion proteins on the surface of filamentous phage. In particular, a single vector can be used for generating cell and phage libraries containing a given series of protein sequences fused to either one or other of two phage coat proteins. This approach simplifies and improves the efficiency of the subsequent phage display-based selection of protein-binding molecules having therapeutic or diagnostic utility, such as antibodies, peptides, or epitope-binding regions.
    Type: Grant
    Filed: July 6, 2006
    Date of Patent: October 12, 2010
    Assignee: Ribovax Biotechnologies SA
    Inventors: Roberto Burioni, Massimo Clementi
  • Publication number: 20100143376
    Abstract: The present invention provides novel antibody sequences that bind and neutralize Rubella Virus (RuV). The novel sequences can be used for the medical management of RuV infection, in particular for detecting the virus or for preparing pharmaceutical compositions. The RuV-specific antigens recognized by such antibody sequences can be identified using novel phage libraries that display peptides.
    Type: Application
    Filed: March 6, 2008
    Publication date: June 10, 2010
    Applicant: RIBOVAX BIOTECHNOLOGIES S.A.
    Inventors: Roberto Burioni, Massimo Clementi